Last reviewed · How we verify

NCT05128422

Normobaric Hyperoxia Combined With Endovascular Treatment for Acute Ischemic Stroke

Completed NA Last updated 31 July 2024
What this trial tests

NA trial testing Normobaric oxygen therapy in Stroke in 120 participants. Completed in 15 October 2023.

Timeline
27 October 2021
Primary endpoint
15 October 2023
15 October 2023

Quick facts

Lead sponsorCapital Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment120
Start date27 October 2021
Primary completion15 October 2023
Estimated completion15 October 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Capital Medical University

Who can join

18 and older, any sex, with Stroke or Endovascular Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficiency of normobaric hyperoxia combined with endovascular treatment for acute ischemic stroke patients with stroke onset 6-24 hours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Normobaric oxygen therapy

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Capital Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05128422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing